<DOC>
	<DOCNO>NCT01734785</DOCNO>
	<brief_summary>This trial compare use two different dos Empagliflozin placebo , T2DM patient 16 wks linagliptin treatment metformin background therapy .</brief_summary>
	<brief_title>Safety Efficacy Combination Empagliflozin Linagliptin Compared Linagliptin Alone Over 24 Weeks Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus . 2 . Male female patient diet exercise regimen , pretreated immediate release metformin least 12 week , patient dose high equal 1500 mg/day metformin , maximum tolerate dose , maximum dose per local label . 3 . HbA1c high equal 8.0 % low equal 10.5 % screen visit . 4 . Age 18 year screen . 5 . Body Mass Index lower equal 45 kg/m2 screen visit . 6 . Signed date write informed consent . Exclusion criterion : 1 . Uncontrolled hyperglycemia glucose level 270 mg/dl ( 15 mmol/dl ) overnight fast . 2 . Use antidiabetic drug ( except metformin background therapy ) . 3 . Acute coronary syndrome , stroke TIA within 3 month prior inform consent . 4 . Indication liver disease . 5 . Impaired renal function . 6 . Gastrointestinal surgery . 7 . Treatment antiobesity drug within 3 month prior screen , treatment time screen ( i.e . surgery , aggressive diet regimen , etc . ) lead unstable body weight . 8 . Current treatment systemic steroid time inform consent uncontrolled endocrine disorder except type 2 diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>